The effect of clarithromycin to prolong the survival time of patients with unresectable non-small lung cancer.
|
Accession number;00A0333861
|
| Title;The effect of clarithromycin to prolong the survival time of patients with unresectable non-small lung cancer. |
| Author;
SAKAMOTO MASAHIRO
(Nara Med. Univ.)
MIKASA KEIICHI
(Nara Med. Univ.)
MAJIMA TOSHIMASA
(Nara Med. Univ.)
KONISHI MITSURU
(Nara Med. Univ.)
MAEDA KOICHI
(Nara Med. Univ.)
YOSHIMOTO EIICHIRO
(Nara Med. Univ.)
MURAKAWA KOICHI
(Nara Med. Univ.)
KITA EIJI
(Nara Med. Univ.)
NARITA NOBUHIRO
(Nara Med. Univ.)
|
Journal Title;Japanese Journal of Chemotherapy
|
Journal Code:F0608A
|
ISSN:1340-7007
|
|
VOL.48;NO.2;PAGE.112-116(2000)
|
| Figure&Table&Reference;FIG.6, TBL.1, REF.16 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;As we have previously reported, clarithromycin(CAM), a 14-membered ring macrolide, is BRM active, and prolongs the survival time for patients with unresectable non-small cell lung cancer without impairing quality of life. In this study, we have evaluated retrospectively 119 patients with non-small cell lung cancer who were administered CAM, and compared the factors affecting survival between the responder group (11 patients who enjoyed longer survival and were administered CAM for more than 24 months) and the non-responder group (25 patients who were administered CAM for less than 6 months). The median survival time was 63 weeks in all patients, 78 weeks in patients with squamous cell carcinoma, 49 weeks in adenocarcinoma, and 68 weeks in large cell carcinoma. In the responder group, the number of patients with squamous cell carcinoma was 8 (73%), and that of patients with clinical stage IV was 3 (27%). Regarding the basic therapy, one patient received chemotherapy only, and 9 patients (82%) received basic therapy, including radiotherapy, in the responder group. In the non-responder group, however, 9 patients (36%) received chemotherapy only, and 12 patients (48%) received basic therapy, including radiotherapy. In the responder group, many patients had good performance status(PS), and significant increase in the body weight, and in the levels of hemoglobin, cholinesterase, and albumin. However, the non-responder group, showed no significant changes.... (author abst.) |
|
|
|
Related Articles;
|
|
